Antisense therapy targeting apolipoprotein (a): a randomised, double-blind, placebo-controlled phase 1 study

…, W Singleton, MJ Graham, BF Baker, JL Burkey… - The Lancet, 2015 - thelancet.com
Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic
valve stenosis. No effective therapies to lower plasma Lp(a) concentrations exist. We have …

Cytotoxicity and genotoxicity of methyleugenol and related congeners—a mechanism of activation for methyleugenol

JL Burkey, JM Sauer, CA McQueen, IG Sipes - … Research/Fundamental and …, 2000 - Elsevier
Methyleugenol is a substituted alkenylbenzene found in a variety of foods, products, and
essential oils. In a 2-year bioassay conducted by the National Toxicology Program, …

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of …

LM Rorick-Kehn, BG Johnson, JL Burkey… - … of Pharmacology and …, 2007 - ASPET
Group II metabotropic glutamate (mGlu) receptor agonists, including (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate
monohydrate (LY354740) and (–)-2-oxa-4-…

In vivo metabolism of [14C] ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid …

…, M Zmijewski, P Yi, DD O'Bannon, JL Burkey… - Drug metabolism and …, 2006 - ASPET
Ruboxistaurin (LY333531), a potent and isoform-selective protein kinase C β inhibitor, is
currently undergoing clinical trials as a therapeutic agent for the treatment of diabetic …

Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin‐mediated CYP3A4 induction

…, MT Lim, JR Voelker, JL Burkey… - British journal of …, 2006 - Wiley Online Library
Aims The aim of this study was to evaluate the effect of rifampicin co‐administration on the
pharmacokinetics of ruboxistaurin and its active metabolite, N‐desmethyl ruboxistaurin and, in …

Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC–MS/MS

Y Wang, Y Qu, CL Bellows, JS Ahn, JL Burkey… - Bioanalysis, 2012 - Future Science
Background: Davalintide, an investigational therapeutic peptide for the treatment of obesity,
is rapidly metabolized by enzymatic cleavage of its N-terminal lysine residue to produce an …

Disposition of [14C] ruboxistaurin in humans

JL Burkey, KM Campanale, R Barbuch… - Drug metabolism and …, 2006 - ASPET
Ruboxistaurin is a potent and specific inhibitor of the β isoforms of protein kinase C (PKC)
that is being developed for the treatment of diabetic microvascular complications. The …

Toxicity of the heterocyclic amine batracylin: investigation of rodent N-acetyltransferase activity and potential contribution of cytochrome P450 3A

GJ Stevens, JL Burkey, CA McQueen - Cell biology and toxicology, 2000 - Springer
The heterocyclic amine, batracylin (BAT), is genotoxic and several lines of evidence suggest
that acetylation is one step in the formation of a DNA-damaging product. The variation in …

Disposition of LY333531, a selective protein kinase C β inhibitor, in the Fischer 344 rat and beagle dog

JL Burkey, KM Campanale, DD O'bannon… - Xenobiotica, 2002 - Taylor & Francis
1. Studies were conducted in the Fischer 344 rat and beagle dog to determine the disposition
of LY333531 and its equipotent active des-methyl metabolite, LY338522, both potent and …

[BOOK][B] Electronic commerce education: An analysis of practitioner and academic perceptions of essential skills and knowledge

JL Burkey - 2002 - search.proquest.com
INFORMATION TO USERS Page 1 INFORMATION TO USERS This manuscript has been
reproduced from the microfilm master. UMI films the text directly from the original or copy …